Your search for "" return 194 results.
Ceva Animal Health and Touchlight sign an agreement to use Touchlight’s dbDNA technology in animal health >
Ceva and Touchlight entered into an agreement and a long-term collaboration for the development and manufacture of new dbDNA vaccines and therapeutics across a broad range of animal health indications...
Ceva Names New SVP for North America >
Brad McCollum will lead Ceva’s business in the United States and Canada.
Seeking Projects Advancing Human-Animal Bond >
Event seeks innovative solutions for the well-being and care of companion animals and their pet parents.
PANOQUELL®-CA1 (fuzapladib sodium for injection) is now available in the U.S. >
The first and only drug conditionally approved by the FDA for management of the symptoms associated with acute onset of canine pancreatitis
WVA Global Veterinary Awards launched >
New awards recognize work in One Health, Animal Welfare, Medicine Stewardship and Veterinary Education
Ceva Launches Wildlife Research Fund >
Ceva Wildlife Research Fund, the first endowment fund dedicated to research to protect wildlife.
Terms and Conditions >
TERMS AND CONDITIONS OF SALE
U.S. Jobs >
We are currently seeking candidates for a variety of positions
CEVA EXPANDS ORAL RABIES VACCINE PORTFOLIO WITH THE ACQUISITION OF CANADIAN FIRM ARTEMIS TECHNOLOGIES, INC. >
Libourne, May 16, 2022 – Ceva Santé Animale (Ceva) has acquired the Canadian oral rabies vaccine manufacturer Artemis Technologies, Inc. Artemis, located in Guelph, ON, Canada, produces ONRAB®, a ra...
Program Receives Quality Recognition >
Ceva’s U.S. C.H.I.C.K Program receives independently audited quality recognition from Bureau Veritas